NuVasive Future Growth
Future criteria checks 3/6
NuVasive is forecast to grow earnings and revenue by 46.2% and 6.7% per annum respectively. EPS is expected to grow by 44.6% per annum. Return on equity is forecast to be 14.3% in 3 years.
Key information
46.2%
Earnings growth rate
44.6%
EPS growth rate
| Medical Equipment earnings growth | 17.1% |
| Revenue growth rate | 6.7% |
| Future return on equity | 14.3% |
| Analyst coverage | Good |
| Last updated | 01 Sep 2023 |
Recent future growth updates
Recent updates
Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?
Apr 18
What Does NuVasive, Inc.'s (NASDAQ:NUVA) Share Price Indicate?
Jan 24NuVasive, Inc.'s (NASDAQ:NUVA) Intrinsic Value Is Potentially 48% Above Its Share Price
Dec 31Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal
Dec 05These 4 Measures Indicate That NuVasive (NASDAQ:NUVA) Is Using Debt Reasonably Well
Nov 13Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)
Sep 22Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal
Sep 01NuVasive Likely Undervalued, But It's Hard To Find Catalysts
Aug 17Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?
Aug 11NuVasive Non-GAAP EPS of $0.47 misses by $0.09, revenue of $310.5M beats by $4.12M
Aug 03NuVasive: Industry Tailwinds More Than Fairly Priced
Jun 13Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)
Jun 01Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital
May 11NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet
Apr 20At US$56.32, Is NuVasive, Inc. (NASDAQ:NUVA) Worth Looking At Closely?
Mar 30NuVasive's Turnaround Story Needs A Boost From Better Results
Mar 01Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital
Dec 28Should You Think About Buying NuVasive, Inc. (NASDAQ:NUVA) Now?
Dec 02NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet
Nov 11NuVasive, Inc. (NASDAQ:NUVA) Shares Could Be 32% Below Their Intrinsic Value Estimate
Oct 21Be Wary Of NuVasive (NASDAQ:NUVA) And Its Returns On Capital
Sep 29At US$59.79, Is It Time To Put NuVasive, Inc. (NASDAQ:NUVA) On Your Watch List?
Aug 18NuVasive Still Getting No Love With COVID-19 And Competitive Worries
Aug 12Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?
Jul 27Are Investors Undervaluing NuVasive, Inc. (NASDAQ:NUVA) By 21%?
Jun 17Some Investors May Be Worried About NuVasive's (NASDAQ:NUVA) Returns On Capital
May 30Why We Think NuVasive, Inc.'s (NASDAQ:NUVA) CEO Compensation Is Not Excessive At All
May 12Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?
Mar 30Is Now The Time To Look At Buying NuVasive, Inc. (NASDAQ:NUVA)?
Mar 09Need To Know: NuVasive, Inc. (NASDAQ:NUVA) Insiders Have Been Buying Shares
Feb 16
A Look At The Fair Value Of NuVasive, Inc. (NASDAQ:NUVA)
Jan 26NuVasive stock gains on study results of its X360 surgery approach
Jan 06What Type Of Returns Would NuVasive's(NASDAQ:NUVA) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Jan 05Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 1,452 | 91 | 114 | 289 | 8 |
| 12/31/2024 | 1,360 | 73 | 107 | 233 | 12 |
| 12/31/2023 | 1,279 | 38 | 63 | 214 | 12 |
| 6/30/2023 | 1,226 | 28 | -3 | 140 | N/A |
| 3/31/2023 | 1,219 | 20 | 23 | 165 | N/A |
| 12/31/2022 | 1,202 | 40 | 30 | 169 | N/A |
| 9/30/2022 | 1,199 | -20 | 27 | 160 | N/A |
| 6/30/2022 | 1,174 | -40 | 44 | 171 | N/A |
| 3/31/2022 | 1,159 | -37 | 38 | 157 | N/A |
| 12/31/2021 | 1,139 | -64 | 70 | 182 | N/A |
| 9/30/2021 | 1,129 | -26 | 103 | 217 | N/A |
| 6/30/2021 | 1,153 | 2 | 122 | 232 | N/A |
| 3/31/2021 | 1,062 | -50 | 107 | 212 | N/A |
| 12/31/2020 | 1,051 | -37 | 76 | 186 | N/A |
| 9/30/2020 | 1,069 | -9 | 78 | 188 | N/A |
| 6/30/2020 | 1,065 | -4 | 62 | 175 | N/A |
| 3/31/2020 | 1,153 | 61 | 96 | 216 | N/A |
| 12/31/2019 | 1,168 | 65 | 105 | 235 | N/A |
| 9/30/2019 | 1,146 | 48 | 104 | 229 | N/A |
| 6/30/2019 | 1,127 | 52 | 115 | 235 | N/A |
| 3/31/2019 | 1,116 | 49 | 89 | 207 | N/A |
| 12/31/2018 | 1,102 | 12 | 110 | 219 | N/A |
| 9/30/2018 | 1,085 | 24 | 109 | 209 | N/A |
| 6/30/2018 | 1,060 | 41 | 84 | 187 | N/A |
| 3/31/2018 | 1,038 | 42 | 77 | 185 | N/A |
| 12/31/2017 | 1,027 | 82 | 64 | 177 | N/A |
| 9/30/2017 | 1,027 | 64 | 65 | 179 | N/A |
| 6/30/2017 | 1,019 | 35 | 17 | 123 | N/A |
| 3/31/2017 | 996 | 53 | N/A | 127 | N/A |
| 12/31/2016 | 962 | 37 | N/A | 158 | N/A |
| 9/30/2016 | 906 | 42 | N/A | 137 | N/A |
| 6/30/2016 | 867 | 51 | N/A | 154 | N/A |
| 3/31/2016 | 834 | 31 | N/A | 120 | N/A |
| 12/31/2015 | 811 | 66 | N/A | 89 | N/A |
| 9/30/2015 | 800 | 62 | N/A | 67 | N/A |
| 6/30/2015 | 790 | 47 | N/A | 102 | N/A |
| 3/31/2015 | 777 | 33 | N/A | 118 | N/A |
| 12/31/2014 | 762 | -17 | N/A | 116 | N/A |
| 9/30/2014 | 749 | -18 | N/A | 124 | N/A |
| 6/30/2014 | 728 | -9 | N/A | 113 | N/A |
| 3/31/2014 | 703 | -11 | N/A | 97 | N/A |
| 12/31/2013 | 685 | 8 | N/A | 97 | N/A |
| 9/30/2013 | 660 | -1 | N/A | 101 | N/A |
| 6/30/2013 | 639 | -6 | N/A | 97 | N/A |
| 3/31/2013 | 628 | 3 | N/A | 114 | N/A |
| 12/31/2012 | 620 | 3 | N/A | 130 | N/A |
| 9/30/2012 | 605 | -4 | N/A | 109 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NUVA's forecast earnings growth (46.2% per year) is above the savings rate (2.2%).
Earnings vs Market: NUVA's earnings (46.2% per year) are forecast to grow faster than the US market (14.9% per year).
High Growth Earnings: NUVA's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: NUVA's revenue (6.7% per year) is forecast to grow slower than the US market (8.1% per year).
High Growth Revenue: NUVA's revenue (6.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NUVA's Return on Equity is forecast to be low in 3 years time (14.3%).